title: Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.
abstract: Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. We conducted a Medline literature search to identify rosuvastatin papers published in English. In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety. We also review the major clinical trials with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other statins. Finally we address its place in clinical practice.
authors.affiliation: Department of Clinical Biochemistry, Leeds General Infirmary, LS1 3EX.
authors.forename: Ahai
authors.initials: A
authors.lastname: Luvai
authors.forename: Wycliffe
authors.initials: W
authors.lastname: Mbagaya
authors.forename: Alistair S
authors.initials: AS
authors.lastname: Hall
authors.forename: Julian H
authors.initials: JH
authors.lastname: Barth